Study title: Interferon gamma-1b (IF-RC 1001 XX G): Safety, Efficacy and Pharmaco- kinetics of 0.1 mg/sqm, 0.25 mg/sqm and 0.5 mg/sqm Interferon gamma-1b for 2 or more Weeks Sub- cutaneaously Administered to Patients with Lympho- mas, Plasmo- cytomas and Solid Tumors.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Neoplasms [C04] | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: INTERFERON GAMMA (1B) | |||||
ATC code: | |||||
Document link: | |||||
Document date: | |||||
Study number: EBI 4.20,IP 137.3,137.3 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | - |